Change Healthcare Inc. Reports Third Quarter Fiscal 2020 Financial Results
NASHVILLE, Tenn.–(BUSINESS WIRE)–Change Healthcare Inc. (Nasdaq: CHNG), a leading independent healthcare technology company, today reported financial results for Change Healthcare LLC (“Change Healthcare”) for the third quarter of fiscal year 2020 ended December 31, 2019.
“The team delivered another quarter of strong financial and operational results, highlighting the momentum and success we are seeing in the market,” said Neil de Crescenzo, president and chief executive officer. “Positive trends in the market for innovation and operational efficiency are continuing to drive demand for existing and new solutions, which are leveraging our investments in artificial intelligence, API’s and native cloud-based initiatives. We believe we are well-positioned to drive growth throughout the remainder of Fiscal 2020 and beyond supported by a healthy pipeline, and we look forward to partnering with our customers to reduce cost, increase quality, and enhance their ability to drive consumer engagement.”
Adoption of the New Revenue Recognition Standard – ASC 606
Change Healthcare adopted the new revenue recognition accounting standard Accounting Standards Codification (“ASC”) 606 effective April 1, 2019 on a modified retrospective basis. Financial results for reporting periods during fiscal year 2020 are presented in compliance with the new revenue recognition standard. Historical financial results for reporting periods prior to fiscal year 2020 are presented in conformity with the prior revenue recognition standard, ASC 605. This press release includes additional information to reconcile the impacts of the adoption of the new revenue recognition standard on Change Healthcare’s financial results for the quarter and nine months ended December 31, 2019. This includes the presentation of financial results during fiscal year 2020 under ASC 605 for comparison to the prior-year period.
Fiscal 2020 Third Quarter Highlights for Change Healthcare LLC:
Financial Summary – ASC 606 (standard adopted effective April 1, 2019)
- Total revenue of $808.2 million, including solutions revenue of $752.5 million
- Net income of $31.2 million, resulting in net income of $0.10 per diluted unit(1)
- Adjusted net income of $106.3 million, resulting in adjusted net income of $0.33 per diluted unit(1)
- Adjusted EBITDA of $232.6 million
Financial Summary – ASC 605 (standard before April 1, 2019)
- Total revenue of $832.2 million, including solutions revenue of $776.5 million
- Net income of $49.0 million, resulting in net income of $0.15 per diluted unit(1)
- Adjusted net income of $124.1 million, resulting in adjusted net income of $0.39 per diluted unit(1)
- Adjusted EBITDA of $250.3 million
|
(1) |
Common units of Change Healthcare LLC are equivalent to the number of outstanding common shares of Change Healthcare Inc. and membership interests of Change Healthcare LLC held by subsidiaries of McKesson. |
Financial Results – ASC 606 (standard adopted effective April 1, 2019)
- Solutions revenue was $752.5 million. Third-quarter results were impacted by the adoption of the new accounting standard, ASC 606, which resulted in the recognition of certain revenue in the first quarter of the fiscal year that would have been recognized in the subsequent periods under the prior accounting rules. The third-quarter results reflect an unfavorable revenue impact of $24.0 million as compared with ASC 605.
- Net income was $31.2 million, resulting in net income of $0.10 per diluted unit. Net income under the new accounting standard was impacted favorably by an extended recognition period for commissions and certain implementation costs, decreasing expenses in the period by $6.3 million, partially offsetting the revenue impact of ASC 606 noted above.
- Adjusted net income was $106.3 million, resulting in adjusted net income of $0.33 per diluted unit.
- Adjusted EBITDA was $232.6 million. Adjusted EBITDA as a percent of Solutions revenue for the third quarter of fiscal 2020 was 30.9%.
Financial Results – ASC 605 (standard before April 1, 2019)
- Solutions revenue was $776.5 million, compared to $763.1 million for the third quarter of fiscal 2019. Total revenue for the current period, which includes Postage revenue, was $832.2 million, compared to $821.9 million in the same period of the prior fiscal year. Growth in both the Software & Analytics and Network Solutions businesses was partially offset by the impact of planned contract eliminations in our Technology-Enabled Services business, and the impact of our optimization initiatives in our Connected Analytics business. As part of our stated strategy, we are repositioning certain of our Revenue Cycle Management (“RCM”) service solutions to better address end-market dynamics, enhance efficiency and to improve the long-term growth potential of these solutions.
- Net income was $49.0 million, resulting in net income of $0.15 per diluted unit, compared with net income of $13.0 million or $0.05 per diluted unit, respectively, for the third quarter of fiscal 2019. During the third quarter of fiscal 2020, the favorable impact of productivity improvements and growth across our Software & Analytics and Network Solutions businesses was partially offset by planned contract eliminations in our Technology-Enabled Service business.
- Adjusted net income was $124.1 million, resulting in adjusted net income of $0.39 per diluted unit, compared with adjusted net income of $96.4 million or $0.38 per diluted unit, respectively, for the third quarter of fiscal 2019. Net income per unit and Adjusted net income per unit for the current period is based on 322 million units compared to 253 million units in the prior year increasing as a result of the initial public offering completed on July 1, 2019.
- Adjusted EBITDA was $250.3 million, compared with $234.1 million for the third quarter of fiscal 2019. Adjusted EBITDA as a percent of Solutions revenue for the third quarter of fiscal 2020 was 32.2%, compared with 30.7% for the third quarter of fiscal 2019. The improved performance was the result of a favorable impact of mix, productivity improvements and growth across our segments.
Cash Flow and Balance Sheet Highlights for Change Healthcare LLC:
Net cash provided by operating activities was $401.0 million for the nine months ended December 31, 2019, an increase of 61.1% from $248.8 million for the nine months ended December 31, 2018. Free cash flow was $213.8 million for the nine months ended December 31, 2019, an increase of 265.0% from $58.6 million for the nine months ended December 31, 2018. Adjusted free cash flow was $324.9 million, an increase of $74.7 million year over year.
Net cash provided by operating activities, free cash flow, and adjusted free cash flow each is affected by pass-thru funds we receive from certain pharmaceutical industry participants in advance of our obligation to remit these funds to participating retail pharmacies. Such pass-thru funds were $1.8 million for the nine months ended December 31, 2019 and $37.1 million for the nine months ended December 31, 2018. The increase in cash flow from operations, free cash flow, and adjusted free cash flow in the current period primarily resulted from improved working capital driven by lower receivable balances and reduced integration capital expenditures.
Change Healthcare LLC ended the quarter with approximately $74.5 million of cash, cash equivalents, and restricted cash and approximately $4,828.0 million of total debt. During the quarter, Change Healthcare LLC repaid $150.0 million in term loan facility obligations.
As of December 31, 2019, no amounts had been drawn under the revolving credit facility.
Recent Business Highlights
- Launched Provider-Payer Data Exchange Solution, the industry’s first nationwide solution to enable providers to submit documents and data, such as claims attachments, electronically to all payers in both the Medical and Workers’ Compensation market segments.
- Unveiled API & Services Connection™, a marketplace for open, standards-based application programming interface (API) products powered by the AWS Marketplace. Through this marketplace, any healthcare organization can leverage the same capabilities that power the company’s industry-leading healthcare financial, clinical, and engagement solutions.
- Announced four leading providers as development partners to build and implement our cloud-native Enterprise Imaging Network on the Google Cloud Platform. Built from the ground up to exploit the flexible nature of cloud services and delivery, the network will enhance and optimize medical imaging data—enabling providers to improve clinical, financial, and operational outcomes.
- Integrated Change Healthcare’s InterQual Connect™ Medical Review Service and InterQual AutoReview™ into Cerner Corporation’s Acute Case Management (ACM) solution and electronic health record (EHR). Through the enhanced workflow from these capabilities, Cerner clients can help their case managers more easily and efficiently prioritize patients’ needs.
Full Year Fiscal 2020 Outlook and 2021 Guidance – ASC 606
For full-year fiscal 2020, Change Healthcare continues to expect Solutions revenue growth of 1% to 2% excluding the revenue from the sale of our extended care business in fiscal year 2019 and including the impact of planned contract exits; Adjusted EBITDA growth of 6% to 8% and Adjusted net income growth of 9% to 11%. Free cash flow is expected to be in the range of $250 million to $300 million.
For fiscal year 2021, the company continues to expect Solutions revenue growth of 4% to 6% and Adjusted EBITDA growth of 6% to 8%.
Fourth Quarter Fiscal 2020 Guidance – ASC 606
Change Healthcare expects fourth-quarter fiscal 2020 Solutions revenue in the range of $775 million to $785 million, Adjusted EBITDA in the range of $260 million to $270 million, and Adjusted net income in the range of $115 million to $125 million.
Per our prior guidance, full-year revenue was not previously expected to differ materially between the two accounting standards but based on the incremental ASC 606 impact in the third quarter, we now anticipate the full-year impact to be an approximately $6 million decrease in revenue for the year. The impact from extended recognition periods for commission expense as a result of the adoption of ASC 606 is expected to be favorable by about $4 million pre-tax for the fourth quarter of fiscal 2020.
A reconciliation of the forward-looking fourth-quarter and full-year fiscal 2020 and 2021 Adjusted EBITDA outlook to net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, Change Healthcare LLC is unable to assess the probable significance of the unavailable information, which could have a material impact on its future financial results in accordance with generally accepted accounting principles in the United States of America (“GAAP”).
Conference Call and Webcast Information
Change Healthcare will host a conference call on February 13, 2020, at 8:00 a.m. ET. Investors and other interested parties are invited to listen to the conference call by dialing 1-(877) 279-0788 in the U.S.; 1-(270) 215-9894 from abroad, including the conference ID number: 2298629; or via a live, audio webcast on the Company’s website at https://ir.changehealthcare.com/.
A webcast replay will be available for on-demand listening shortly after the completion of the call until the third-quarter fiscal 2021 earnings call, at the aforementioned URL. In addition, a digital audio playback will be available until 11:00 a.m. Eastern Time on Thursday, February 20, 2020, by dialing 1-(855) 859-2056 or 1-(404) 537-3406 and referencing confirmation 2298629.
About Change Healthcare
Change Healthcare (Nasdaq: CHNG) is a leading independent healthcare technology company that provides data and analytics-driven solutions to improve clinical, financial and patient engagement outcomes in the U.S. healthcare system. We are a key catalyst of a value-based healthcare system, accelerating the journey toward improved lives and healthier communities. Learn more at changehealthcare.com.
CHNG-IR
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of federal securities laws. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include information concerning possible or assumed future results of operations, including our guidance and descriptions of our business plans and strategies. These statements often include words such as “anticipate,” “expect,” “suggest,” “plan,” “believe,” “intend,” “estimate,” “target,” “project,” “should,” “could,” “would,” “may,” “will,” “forecast,” “outlook,” “potential,” “continues,” “seeks,” “predicts,” and the negatives of these words and other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties, including factors disclosed in the Registration Statement on Form S-1 (No. 333-230345) in the section entitled “Risk Factors,” as such factors may be updated from time to time in our periodic filings with the SEC, and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these uncertainties, you should not place undue reliance on any forward-looking statements in this release. All forward-looking statements are based on information currently available to Change Healthcare and are qualified in their entirety by this cautionary statement. The statements herein speak only as of the date such statements were first made. Except to the extent required by law, Change Healthcare assumes no obligation to update any such forward-looking statements or other statements included in this release.
Non-GAAP Financial Measures
In the company’s earnings releases, prepared remarks, conference calls, slide presentations and webcasts, there may be use or discussion of non-GAAP financial measures. We believe such measures provide supplemental information to investors with regard to our operating performance and assist investors’ ability to compare our financial results to those of other companies in the same industry. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between the comparable GAAP financial measure and each non-GAAP financial measure are included in this press release after the consolidated financial statements. These non-GAAP financial measures are calculated and presented on the basis of methodologies other than in accordance with GAAP. These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP and may be defined and calculated differently by others in the same industry.
|
|
|
|
|
|
|
|
|
|
||||||||
|
Change Healthcare Inc. Statements of Operations (unaudited and amounts in thousands, except share and per share amounts) |
||||||||||||||||
|
|
|
|
|
|
|
|
||||||||||
|
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
December 31, |
|
December 31, |
||||||||||||
|
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
||||||||
|
Revenue |
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
||||
|
Operating expenses |
|
|
|
|
|
|
|
|
||||||||
|
General and administrative |
|
1,115 |
|
|
126 |
|
|
2,504 |
|
|
188 |
|
||||
|
Accretion Expense |
|
(1,191 |
) |
|
— |
|
|
47,172 |
|
|
— |
|
||||
|
Total operating expenses |
|
(76 |
) |
|
126 |
|
|
49,676 |
|
|
188 |
|
||||
|
Operating income (loss) |
|
76 |
|
|
(126 |
) |
|
(49,676 |
) |
|
(188 |
) |
||||
|
Non-operating (income) expense |
|
|
|
|
|
|
|
|
||||||||
|
Loss from Equity Method Investment in the Joint Venture |
|
8,764 |
|
|
17,468 |
|
|
104,497 |
|
|
65,805 |
|
||||
|
(Gain) Loss on Sale of Interests in the Joint Venture |
|
— |
|
|
— |
|
|
— |
|
|
(661 |
) |
||||
|
Management fee income |
|
(771 |
) |
|
(126 |
) |
|
(1,648 |
) |
|
(188 |
) |
||||
|
Interest expense |
|
602 |
|
|
— |
|
|
1,246 |
|
|
— |
|
||||
|
Interest income |
|
(601 |
) |
|
— |
|
|
(1,245 |
) |
|
— |
|
||||
|
Amortization of debt discount and issuance costs |
|
191 |
|
|
— |
|
|
403 |
|
|
— |
|
||||
|
Unrealized (gain) loss on forward purchase contract |
|
(74,084 |
) |
|
— |
|
|
(71,649 |
) |
|
— |
|
||||
|
Total non-operating (income) expense |
|
(65,899 |
) |
|
17,342 |
|
|
31,604 |
|
|
64,956 |
|
||||
|
Income (loss) before income tax provision (benefit) |
|
65,975 |
|
|
(17,468 |
) |
|
(81,280 |
) |
|
(65,144 |
) |
||||
|
Income tax provision (benefit) |
|
15,240 |
|
|
(5,080 |
) |
|
(564 |
) |
|
(16,664 |
) |
||||
|
Net income (loss) |
$ |
50,735 |
|
$ |
(12,388 |
) |
$ |
(80,716 |
) |
$ |
(48,480 |
) |
||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Net income (loss) per share: |
|
|
|
|
|
|
|
|
||||||||
|
Basic |
$ |
0.35 |
|
$ |
(0.16 |
) |
$ |
(0.67 |
) |
$ |
(0.64 |
) |
||||
|
Diluted |
$ |
0.35 |
|
$ |
(0.16 |
) |
$ |
(0.67 |
) |
$ |
(0.64 |
) |
||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Weighted average shares |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Basic |
|
143,392,295 |
|
|
75,465,310 |
|
|
120,657,859 |
|
|
75,525,645 |
|
||||
|
Diluted |
|
146,201,860 |
|
|
75,465,310 |
|
|
120,657,859 |
|
|
75,525,645 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
||
|
Change Healthcare Inc. Balance Sheets (unaudited and amounts in thousands, except share and per share amounts) |
||||||||
|
|
|
|
|
|
|
|
||
|
|
|
December 31, |
|
March 31, |
||||
|
|
|
2019 |
|
2019 |
||||
|
|
|
|
|
|
|
|
||
|
Assets |
|
|
|
|
|
|
||
|
Current Assets: |
|
|
|
|
|
|
||
|
Cash |
|
$ |
3,409 |
|
|
$ |
3,409 |
|
|
Prepaid expenses |
|
|
1,544 |
|
|
|
— |
|
|
Due from the Joint Venture |
|
|
3,429 |
|
|
|
373 |
|
|
Due from McKesson |
|
|
213 |
|
|
|
— |
|
|
Investment in Joint Venture tangible equity units, current |
|
|
15,362 |
|
|
|
— |
|
|
Income taxes receivable |
|
|
1,359 |
|
|
|
1,781 |
|
|
Total current assets |
|
|
25,316 |
|
|
|
5,563 |
|
|
Dividend receivable |
|
|
68,344 |
|
|
|
81,264 |
|
|
Investment in the Joint Venture |
|
|
1,796,512 |
|
|
|
1,211,996 |
|
|
Investment in Joint Venture tangible equity units |
|
|
329,581 |
|
|
|
— |
|
|
Total assets |
|
$ |
2,219,753 |
|
|
$ |
1,298,823 |
|
|
|
|
|
|
|
|
|
||
|
Liabilities and stockholders’ equity |
||||||||
|
Current liabilities: |
|
|
|
|
|
|
||
|
Accounts payable and accrued expenses |
|
$ |
259 |
|
|
$ |
176 |
|
|
Due to the Joint Venture |
|
|
9,806 |
|
|
|
6,167 |
|
|
Current portion of long-term debt |
|
|
15,362 |
|
|
|
— |
|
|
Total current liabilities |
|
|
25,427 |
|
|
|
6,343 |
|
|
Long-term debt |
|
|
23,656 |
|
|
|
— |
|
|
Due to McKesson |
|
|
47,172 |
|
|
|
— |
|
|
Deferred income tax liabilities |
|
|
172,055 |
|
|
|
159,993 |
|
|
Other liabilities |
|
|
1,312 |
|
|
|
— |
|
|
Commitments and contingencies |
|
|
|
|
|
|
||
|
Stockholders’ Equity: |
|
|
|
|
|
|
||
|
Common Stock (par value, $.001), 9,000,000,000 and 252,800,000 shares authorized and 125,027,648 and 75,474,654 shares issued and outstanding at December 31, 2019 and March 31, 2019, respectively |
|
|
124 |
|
|
|
75 |
|
|
Class X common stock (par value, $.001), 1 and 1 share authorized and no shares issued and outstanding at December 31, 2019 and March 31, 2019, respectively |
|
|
— |
|
|
|
— |
|
|
Preferred stock (par value, $.001), 900,000,000 and 0 shares authorized and no shares issued and outstanding at December 31, 2019 and March 31, 2019, respectively |
|
|
— |
|
|
|
— |
|
|
Additional paid-in capital |
|
|
2,016,608 |
|
|
|
1,153,509 |
|
|
Accumulated other comprehensive income (loss) |
|
|
(3,418 |
) |
|
|
(3,256 |
) |
|
Retained earnings (deficit) |
|
|
(63,183 |
) |
|
|
(17,841 |
) |
|
Total stockholders’ equity |
|
|
1,950,131 |
|
|
|
1,132,487 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
2,219,753 |
|
|
$ |
1,298,823 |
|
|
|
|
|
|
|
|
|||
|
Change Healthcare Inc. Statements of Cash Flows (unaudited and amounts in thousands) |
||||||||
|
|
|
|
|
|
||||
|
|
|
Nine Months Ended |
||||||
|
|
|
December 31, |
||||||
|
|
|
2019 |
|
|
2018 |
|||
|
Cash flows from operating activities: |
|
|
|
|
|
|||
|
Net income (loss) |
$ |
(80,716 |
) |
|
$ |
(48,480 |
) |
|
|
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |
|
|
|
|
|
|||
|
Loss from Equity Method Investment in the Joint Venture |
|
104,497 |
|
|
|
65,805 |
|
|
|
Deferred income tax expense (benefit) |
|
(564 |
) |
|
|
(16,664 |
) |
|
|
(Gain) Loss on Sale of Interests in the Joint Venture |
|
— |
|
|
|
(661 |
) |
|
|
(Gain) loss on forward purchase contracts |
|
(71,649 |
) |
|
|
— |
|
|
|
Amortization of debt discount and issuance costs |
|
403 |
|
|
|
— |
|
|
|
Other |
|
1,526 |
|
|
|
— |
|
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|||
|
Prepaid expenses |
|
(1,544 |
) |
|
|
— |
|
|
|
Due from the Joint Venture |
|
(3,056 |
) |
|
|
(188 |
) |
|
|
Due from McKesson |
|
(213 |
) |
|
|
— |
|
|
|
Income taxes receivable |
|
422 |
|
|
|
13,292 |
|
|
|
Accounts payable and accrued expenses |
|
83 |
|
|
|
189 |
|
|
|
Due to McKesson |
|
47,172 |
|
|
|
— |
|
|
|
Due to the Joint Venture |
|
3,639 |
|
|
|
(9,662 |
) |
|
|
Net cash provided by (used in) operating activities |
|
— |
|
|
|
3,631 |
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|||
|
Proceeds from sale of interests in Joint Venture |
|
— |
|
|
|
6,502 |
|
|
|
Investment in debt and equity securities of the Joint Venture |
|
(278,875 |
) |
|
|
— |
|
|
|
Proceeds from investments in debt securities of the Joint Venture |
|
7,332 |
|
|
|
— |
|
|
|
Investment in the Joint Venture |
|
(610,784 |
) |
|
|
— |
|
|
|
Net cash provided by (used in) investing activities |
|
(882,327 |
) |
|
|
6,502 |
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|||
|
Proceeds from initial public offering, net of issuance costs |
|
608,679 |
|
|
|
— |
|
|
|
Proceeds from issuance of equity component of tangible equity units, net of issuance costs |
|
232,929 |
|
|
|
— |
|
|
|
Proceeds from issuance of debt component of tangible equity units |
|
47,367 |
|
|
|
— |
|
|
|
Payment of loan costs |
|
(1,421 |
) |
|
|
— |
|
|
|
Repayment of senior amortizing notes |
|
(7,332 |
) |
|
|
— |
|
|
|
Proceeds from exercise of equity awards |
|
2,105 |
|
|
|
— |
|
|
|
Payments to acquire common stock |
|
— |
|
|
|
(6,502 |
) |
|
|
Net cash provided by (used in) financing activities |
|
882,327 |
|
|
|
(6,502 |
) |
|
|
Net increase (decrease) in cash, cash equivalents and restricted cash |
|
— |
|
|
|
3,631 |
|
|
|
Cash, cash equivalents and restricted cash at beginning of period |
|
3,409 |
|
|
|
— |
|
|
|
Cash, cash equivalents and restricted cash at end of period |
$ |
3,409 |
|
|
$ |
3,631 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Change Healthcare LLC Consolidated Statements of Operations (unaudited and amounts in thousands, except unit and per unit amounts) |
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
December 31, |
|
December 31, |
||||||||||||
|
|
|
2019 |
|
2018 |
|
2019 |
|
|
2018 |
|||||||
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Solutions revenue |
|
$ |
752,533 |
|
|
$ |
763,149 |
|
|
$ |
2,288,305 |
|
|
$ |
2,264,684 |
|
|
Postage revenue |
|
|
55,693 |
|
|
|
58,788 |
|
|
|
171,288 |
|
|
|
180,706 |
|
|
Total revenue |
|
|
808,226 |
|
|
|
821,937 |
|
|
|
2,459,593 |
|
|
|
2,445,390 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Cost of operations (exclusive of depreciation and amortization below) |
|
|
339,413 |
|
|
|
339,485 |
|
|
|
998,943 |
|
|
|
1,007,328 |
|
|
Research and development |
|
|
50,618 |
|
|
|
49,882 |
|
|
151,778 |
|
159,604 |
|
|||
|
Sales, marketing, general and administrative |
|
|
185,661 |
|
|
|
206,558 |
|
|
567,586 |
|
620,612 |
|
|||
|
Customer postage |
|
|
55,693 |
|
|
|
58,788 |
|
|
|
171,288 |
|
|
|
180,706 |
|
|
Depreciation and amortization |
|
|
77,330 |
|
|
|
70,318 |
|
|
226,094 |
|
208,103 |
|
|||
|
Accretion and changes in estimate with related parties, net |
|
|
3,245 |
|
|
|
3,534 |
|
|
|
10,339 |
|
|
|
13,290 |
|
|
Gain on Sale of Business |
|
|
— |
|
|
|
(43 |
) |
|
|
— |
|
|
|
(111,435 |
) |
|
Total operating expenses |
|
|
711,960 |
|
|
|
728,522 |
|
|
|
2,126,028 |
|
|
|
2,078,208 |
|
|
Operating income (loss) |
|
|
96,266 |
|
|
|
93,415 |
|
|
|
333,565 |
|
|
|
367,182 |
|
|
Non-operating (income) and expense |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Interest expense, net |
|
|
66,353 |
|
|
|
82,614 |
|
|
219,661 |
|
241,840 |
|
|||
|
Loss on extinguishment of debt |
|
|
2,514 |
|
|
|
— |
|
|
19,414 |
|
— |
|
|||
|
Contingent consideration |
|
|
900 |
|
|
|
(1,100 |
) |
|
1,809 |
|
(900 |
) |
|||
|
Other, net |
|
|
(2,718 |
) |
|
|
(4,385 |
) |
|
(10,881 |
) |
(13,762 |
) |
|||
|
Total non-operating (income) and expense |
|
|
67,049 |
|
|
|
77,129 |
|
|
|
230,003 |
|
|
|
227,178 |
|
|
Income (loss) before income tax provision (benefit) |
|
|
29,217 |
|
|
|
16,286 |
|
|
|
103,562 |
|
|
|
140,004 |
|
|
Income tax provision (benefit) |
|
|
(1,974 |
) |
|
|
3,277 |
|
589 |
|
1,049 |
|
||||
|
Net income (loss) |
|
$ |
31,191 |
|
|
$ |
13,009 |
|
|
$ |
102,973 |
|
|
$ |
138,955 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net income (loss) per common unit: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Basic |
|
$ |
0.10 |
|
|
$ |
0.05 |
|
|
|
0.35 |
|
|
$ |
0.55 |
|
|
Diluted |
|
$ |
0.10 |
|
|
$ |
0.05 |
|
|
|
0.34 |
|
|
$ |
0.55 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Weighted average common units outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Basic |
|
|
319,387,487 |
|
|
|
251,460,502 |
|
|
|
296,653,051 |
|
|
|
251,520,837 |
|
|
Diluted |
|
|
322,197,051 |
|
|
|
253,318,833 |
|
|
|
300,058,108 |
|
|
|
253,366,866 |
|
|
(1) |
Common units of Change Healthcare LLC are equivalent to the number of outstanding common shares of Change Healthcare Inc. and membership interests of Change Healthcare LLC held by subsidiaries of McKesson. |
Contacts
Evan Smith, CFA
Investor Relations
404-338-2225
Evan.Smith@changehealthcare.com
Kerry Kelly
External Communications
339-236-2756
Kerry.Kelly@changehealthcare.com
